TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34269370

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus/helveticus probiotic
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 32302757

Group type: EXPERIMENTAL
Intervention: Modified Family Navigation (FN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Modified usual care (UC)
Number of subjects: 40
Study: 35354306

Group type: EXPERIMENTAL
Intervention: Atrial shunt device
Number of subjects: 626

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 626
Study: 33785415

Group type: EXPERIMENTAL
Intervention: Sjögren syndrome
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Facial rosacea
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Peripheral artery disease
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Daily smoking history
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Thyroid dysfunction
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Osteoarthritis
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Irritable bowel syndrome
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemia
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: OSDI
Number of subjects: 535
Study: 32862592

Group type: EXPERIMENTAL
Intervention: Endostatin+TAI+TACE
Number of subjects: 96

Group type: COMPARATOR
Intervention: TAI+TACE
Number of subjects: 96
Study: 36278368

Group type: EXPERIMENTAL
Intervention: Walking posture
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Standing posture
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sitting posture
Number of subjects: 16
Study: 34181597

Group type: EXPERIMENTAL
Intervention: Digital animation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Text resources
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 32484914

Group type: EXPERIMENTAL
Intervention: S-1 plus best supportive care (BSC)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 131
Study: 35645222

Group type: EXPERIMENTAL
Intervention: Additional rapid-acting insulin administered at +0h
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Additional rapid-acting insulin administered at +1h
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Additional rapid-acting insulin administered at +2h
Number of subjects: 27

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 27
Study: 33692190

Group type: EXPERIMENTAL
Intervention: Smart agent (SA) system
Number of subjects: 20
Study: 34611745

Group type: EXPERIMENTAL
Intervention: Virtual reality rehabilitation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Optokinetic stimulation rehabilitation
Number of subjects: 60
Study: 33081502

Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring
Number of subjects: 150

Group type: COMPARATOR
Intervention: Traditional self-monitoring of blood glucose (control)
Number of subjects: 150
Study: 35180646

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 33781141

Group type: EXPERIMENTAL
Intervention: BMS‐986020 600 mg once daily (QD)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: BMS‐986020 600 mg twice daily (BID)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 32106642

Group type: EXPERIMENTAL
Intervention: Nebulized heparin (25,000 IU) and salbutamol (5 mg) every 6 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Salbutamol only (5 mg)
Number of subjects: 60
Study: 36471692

Group type: EXPERIMENTAL
Intervention: Remimazolam tosylate plus low-dose propofol (Group RP)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Propofol (Group P)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Remimazolam tosylate (Group R)
Number of subjects: 193
Study: 33757813

Group type: EXPERIMENTAL
Intervention: TST + HIIT
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PT + HIIT
Number of subjects: 35
Study: 34916266

Group type: COMPARATOR
Intervention: Low-dose dexamethasone (6 mg once daily for 10 days)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (20 mg once daily for 5 days, followed by 10 mg once daily for an additional 5 days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low-dose dexamethasone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone
Number of subjects: 200
Study: 32019723

Group type: EXPERIMENTAL
Intervention: MLR-1023 100-mg once-daily (qd)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MLR-1023 100-mg twice-daily (bid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MLR-1023 200-mg once-daily (qd)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MLR-1023 200-mg twice-daily (bid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MLR-1023
Number of subjects: 0
Study: 34062986

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum PS128 probiotic (6 × 10^10 CFUs) + Oxytocin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo + Oxytocin
Number of subjects: 35
Study: 36087806

Group type: EXPERIMENTAL
Intervention: PUSH (specific multi-component intervention)
Number of subjects: 34

Group type: COMPARATOR
Intervention: PULSE (active control, non-specific multi-component intervention)
Number of subjects: 34
Study: 32847638

Group type: EXPERIMENTAL
Intervention: Consumption of ultra-processed foods four times or more a day
Number of subjects: 309
Study: 32931400

Group type: EXPERIMENTAL
Intervention: Olanzapine 0.14 mg/kg/day (maximum 10 mg) during chemotherapy and 3 days postchemotherapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (received aprepitant, ondansetron, and dexamethasone only)
Number of subjects: 240
Study: 34838987

Group type: EXPERIMENTAL
Intervention: Multimodal nonopioid pain regimen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard of care narcotics (opioids)
Number of subjects: 40
Study: 33464688

Group type: EXPERIMENTAL
Intervention: Dobutamine (Db)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal flow group
Number of subjects: 28
Study: 36064571

Group type: EXPERIMENTAL
Intervention: nnU-Net (3D-Cascade U-Net)
Number of subjects: 237
Study: 34582449

Group type: EXPERIMENTAL
Intervention: Group-only delivery model with 16 fortnightly sessions
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Mixed-delivery model combining 12 group sessions with 4 home visits
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1152
Study: 35921688

Group type: EXPERIMENTAL
Intervention: Yoga intervention (12-week duration)
Number of subjects: 0
Study: 32295808

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 321

Group type: COMPARATOR
Intervention: Lixi
Number of subjects: 321
Study: 34953748

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 255

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 255
Study: 32768792

Group type: EXPERIMENTAL
Intervention: Browsing a social networking site (SNS)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Viewing brief movie clips to induce positive, negative, or neutral mood
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control website browsing
Number of subjects: 139
Study: 35170013

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping at 120 seconds
Number of subjects: 68

Group type: COMPARATOR
Intervention: Delayed cord clamping at 30 seconds
Number of subjects: 68
Study: 33508499

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (5-Hz) for 2 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (5-Hz) for 6 months (open-label maintenance phase)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham treatment for 2 weeks
Number of subjects: 44
Study: 35954397

Group type: EXPERIMENTAL
Intervention: Intervention clinic (low-SES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Middle-SES comparison clinics
Number of subjects: 0

Group type: COMPARATOR
Intervention: National level (low-SES)
Number of subjects: 0
Study: 35640080

Group type: EXPERIMENTAL
Intervention: Orthodontic forces applied to test MSPs
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control MSPs (no orthodontic forces applied initially)
Number of subjects: 32
Study: 36153583

Group type: EXPERIMENTAL
Intervention: Atorvastatin (n=27)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n=33)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32729970

Group type: EXPERIMENTAL
Intervention: Technology-based information and coaching/support program
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study: 32732774

Group type: EXPERIMENTAL
Intervention: Always superior partner
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (no partner)
Number of subjects: 41
Study: 35638203

Group type: EXPERIMENTAL
Intervention: Three PRP injections
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: One PRP injection followed by two placebo injections
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo injections (Normal Saline)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Single or multiple PRP injections
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Single PRP injection
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Multiple PRP injections
Number of subjects: 102
Study: 32856285

Group type: EXPERIMENTAL
Intervention: Oral sildenafil (0.5 mg/kg every 6 hours to a target maintenance dose of 2 mg/kg every 6 hours)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone (0.5 μg/kg/min as a continuous infusion)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral sildenafil and intravenous milrinone (dual therapy)
Number of subjects: 60
Study: 33242345

Group type: EXPERIMENTAL
Intervention: Cleanliness prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational presentation (Harm Reduction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational presentation (Healthy Living)
Number of subjects: 0
Study: 34334715

Group type: EXPERIMENTAL
Intervention: PAI e‐Health Program
Number of subjects: 30

Group type: COMPARATOR
Intervention: PA attention control
Number of subjects: 30
Study: 35360742

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation (TEAS)
Number of subjects: 1655

Group type: EXPERIMENTAL
Intervention: Combination of TEAS and palonosetron
Number of subjects: 1655

Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 1655
Study: 33420959

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 35164840

Group type: EXPERIMENTAL
Intervention: Intranasal dexamethasone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Intravenous dexamethasone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (intranasal and intravenous dexamethasone)
Number of subjects: 120
Study: 33381795

Group type: EXPERIMENTAL
Intervention: Soybean oil (SBO)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Cocoa butter (COB)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Palm olein (POo)
Number of subjects: 83
Study: 34482412

Group type: EXPERIMENTAL
Intervention: Ventilator-piloted Pulmonary Recruitment Maneuver (PRM)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Ordinary exsufflation (Control)
Number of subjects: 147
Study: 32366244

Group type: EXPERIMENTAL
Intervention: Lanreotide autogel 60/90/120 mg (monthly deep subcutaneous injection)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Lanreotide 40 mg PR (intramuscular injection every 7, 10, or 14 days)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Lanreotide autogel
Number of subjects: 128

Group type: COMPARATOR
Intervention: Lanreotide 40 mg PR
Number of subjects: 128
Study: 36445529

Group type: EXPERIMENTAL
Intervention: Arabic with high certainty (very-modifier and all-quantifier)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Arabic with low certainty (no very-modifier and some-quantifier)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: English with high certainty
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: English with low certainty
Number of subjects: 368
Study: 32452085

Group type: EXPERIMENTAL
Intervention: Patiromer (8.4 g once daily)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study: 36161759

Group type: EXPERIMENTAL
Intervention: Cumulative BMI exposure (assessed using a quadratic mixed-effects method)
Number of subjects: 19477

Group type: EXPERIMENTAL
Intervention: Weight gain (BMI change: >3%) in baseline BMI <24 kg/m2
Number of subjects: 19477

Group type: EXPERIMENTAL
Intervention: Weight loss (BMI change: <−3%) in baseline BMI ≥24 kg/m2
Number of subjects: 19477

Group type: COMPARATOR
Intervention: Stable weight (BMI change: −3% to 3%)
Number of subjects: 19477
Study: 34159412

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSEA) in left lateral position (Group I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSEA) in sitting position (Group II)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (Group II)
Number of subjects: 100
Study: 35914346

Group type: EXPERIMENTAL
Intervention: Active learning
Number of subjects: 99

Group type: COMPARATOR
Intervention: Formal lectures
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Active learning and Formal lectures
Number of subjects: 99
Study: 34428179

Group type: EXPERIMENTAL
Intervention: Fractionated laser resurfacing (FLR) treatment on one lower arm
Number of subjects: 48

Group type: COMPARATOR
Intervention: Untreated arm (control)
Number of subjects: 48
Study: 33291645

Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 1773

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1773
Study: 35765946

Group type: EXPERIMENTAL
Intervention: HBeAg negative chronic HBV infection patients
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (308 HBsAg negative individuals)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: TyG index and TG/HDL‐C ratio
Number of subjects: 132
Study: 32796016

Group type: EXPERIMENTAL
Intervention: Spraino
Number of subjects: 510

Group type: COMPARATOR
Intervention: do-as-usual
Number of subjects: 510
Study: 34090707

Group type: EXPERIMENTAL
Intervention: Statin use post-diagnosis
Number of subjects: 4207

Group type: EXPERIMENTAL
Intervention: New statin use post-diagnosis
Number of subjects: 4207

Group type: EXPERIMENTAL
Intervention: Continued statin use from before diagnosis
Number of subjects: 4207

Group type: COMPARATOR
Intervention: β-blocker use
Number of subjects: 4207
Study: 33905494

Group type: EXPERIMENTAL
Intervention: Oral doxycycline 200 mg twice daily for 10 days and prednisolone 60 mg once daily for 5 days, then tapered over 5 days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Oral doxycycline (historical control)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both groups underwent follow-up lumbar puncture and were followed until complete recovery or for 12 months
Number of subjects: 57
Study: 32348882

Group type: EXPERIMENTAL
Intervention: Orodispersible film (ODF) 2 x 3 cm
Number of subjects: 150

Group type: COMPARATOR
Intervention: Glucose syrup (0.5-3 mL)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Orodispersible film (ODF)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Glucose syrup
Number of subjects: 150
Study: 35086141

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin and bendamustine plus rituximab (BR)
Number of subjects: 33

Group type: COMPARATOR
Intervention: BR alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Complete response (CR) group (n = 13)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Non-complete response (non-CR) group (n = 10)
Number of subjects: 33
Study: 33190420

Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (resting)
Number of subjects: 47
Study: 35897086

Group type: EXPERIMENTAL
Intervention: iCanCope with PainTM app
Number of subjects: 73

Group type: COMPARATOR
Intervention: Symptom tracking app (control)
Number of subjects: 73
Study: 34862813

Group type: EXPERIMENTAL
Intervention: Sustained nurse home visiting intervention
Number of subjects: 352
Study: 33346444

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 35986615

Group type: EXPERIMENTAL
Intervention: Assar's technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shehata's technique
Number of subjects: 0
Study: 34342017

Group type: EXPERIMENTAL
Intervention: Choline supplementation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 32176166

Group type: EXPERIMENTAL
Intervention: Trauma Quality of Life Clinic (TQOL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 36
Study: 33269530

Group type: EXPERIMENTAL
Intervention: semaglutide 2.4 mg
Number of subjects: 72
Study: 33260064

Group type: COMPARATOR
Intervention: Lopinavir-Ritonavir (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Huashi Baidu Formula + Lopinavir-Ritonavir (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Huashi Baidu Formula (Group C)
Number of subjects: 60
Study: 33058158

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 11590

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 11590
Study: 36398729

Group type: EXPERIMENTAL
Intervention: Single balloon-assisted colonoscopy (SBC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 44
Study: 33720089

Group type: EXPERIMENTAL
Intervention: Antiviral therapy with oral nucleoside analogue (entecavir or lamivudine) combined with subcutaneous peginterferon alfa-2a from week 8 for 56 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Untreated observation for 80 weeks
Number of subjects: 59
Study: 32171765

Group type: EXPERIMENTAL
Intervention: Intrastromal injection of voriconazole
Number of subjects: 70

Group type: COMPARATOR
Intervention: Topical therapy alone
Number of subjects: 70
Study: 36315917

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus Trastuzumab (P + T) in ERBB2 amplification cohort
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus Trastuzumab (P + T) in ERBB2/3 mutation cohort
Number of subjects: 38
Study: 33727642

Group type: EXPERIMENTAL
Intervention: Amino acid beverage lacking dopamine precursors
Number of subjects: 34

Group type: COMPARATOR
Intervention: Balanced amino acid beverage (control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dopamine precursor depletion procedure
Number of subjects: 34
Study: 35838778

Group type: EXPERIMENTAL
Intervention: EEG accompanied by medical clowns (study group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine EEG without medical clowns (control group)
Number of subjects: 100
Study: 33279173

Group type: EXPERIMENTAL
Intervention: LCP
Number of subjects: 78

Group type: COMPARATOR
Intervention: ABP
Number of subjects: 78
Study: 34985237

Group type: COMPARATOR
Intervention: Hip and knee strengthening at 70% of 1 repetition maximum
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Strengthening with blood flow restriction at 30% of 1 repetition maximum at 70% of limb occlusion pressure
Number of subjects: 60
Study: 34578906

Group type: EXPERIMENTAL
Intervention: Cannabidiol supplementation (CBD)
Number of subjects: 21
Study: 32660512

Group type: EXPERIMENTAL
Intervention: Interactive video game-based exercise (IVGB) training during the intervention phase
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control phase (no exercise)
Number of subjects: 24
Study: 35567757

Group type: EXPERIMENTAL
Intervention: Low-dose bicyclol (25 mg TID)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: High-dose bicyclol (50 mg TID)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control (polyenes phosphatidylcholine)
Number of subjects: 241
Study: 33858668

Group type: EXPERIMENTAL
Intervention: Enhanced Enteral Feeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional Feeding
Number of subjects: 0
Study: 36247895

Group type: EXPERIMENTAL
Intervention: Group K (120 kV/40–59 mA/8) for CT imaging
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group i (0.15 mCi/kg/180 s) for PET imaging
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group H (80 kV/40–59 mA/14) for CT scanning
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group g (0.08 mCi/kg/180 s) for PET imaging
Number of subjects: 100
Study: 33387385

Group type: EXPERIMENTAL
Intervention: Depression-specific preventive intervention
Number of subjects: 213

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Slowed gait
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Slowed psychomotor speed
Number of subjects: 213
Study: 36311474

Group type: EXPERIMENTAL
Intervention: SOC + IP
Number of subjects: 72

Group type: COMPARATOR
Intervention: SOC + Placebo
Number of subjects: 72
Study: 35283082

Group type: EXPERIMENTAL
Intervention: Hormonal contraception (various methods including implants, IUDs, combined pills, progestin-only pills, injectables, ring, patch)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Hormonal contraception (various methods)
Number of subjects: 138
Study: 33990145

Group type: EXPERIMENTAL
Intervention: Integrated cardiopulmonary ultrasonography (ICUS)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional treatment (CON)
Number of subjects: 94
Study: 36201384

Group type: EXPERIMENTAL
Intervention: Deposit contract (€10 deposit up front)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Financial reward (€10 contingent on performance)
Number of subjects: 126

Group type: COMPARATOR
Intervention: No-incentive control condition
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Loss frame
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Gain frame
Number of subjects: 126